← Eichor
Study identifier: NCT06393101 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

Condition: Complex Regional Pain Syndrome  ·  Sponsor: University of California, San Diego

PhasePhase 1
Planned participants52
Who can joinAll sexes, 21 Years to 75 Years
Healthy volunteersNo

About this study

The aim of this trial is to determine the potential effects and mechanisms of cannabinoid-induced pain relief in complex regional pain syndrome (CRPS). Multiple psychophysical approaches will be conducted in conjunction with psychological and inflammatory marker testing to determine if and how cannabinoids produce stabilized improvement in CRPS-related pain and comorbidities. The trial consisted of a pre-treatment screening period, six-week treatment period and a two-week follow-up.

This description comes directly from the study's public registry record.

Talk to the study team

Fadel Zeidan, PhD  ·  858-246-8341  ·  fzeidan@health.ucsd.edu

Yasmeen Esshaki, MS  ·  858-246-8341  ·  yesshaki@health.ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Altman Clinical and Translational Research InstituteLa Jolla, California, United StatesRecruiting
University of California, San DiegoSan Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06393101